The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness
Open accessAbstract
BACKGROUND: Human African trypanosomiasis (HAT), also known as sleeping sickness, is a fatal parasitic disease caused by trypanosomes. Current treatment options for HAT are scarce, toxic, no longer effective, or very difficult to administer, in particular for the advanced, fatal stage of the disease (stage 2, chronic HAT). New safe, effective and easy-to-use treatments are urgently needed. Here it is shown that fexinidazole, a 2-substituted 5-nitroimidazole rediscovered by the Drugs for Neglected Diseases initiative (DNDi) after extensive compound mining efforts of more than 700 new and existing nitroheterocycles, could be a short-course, safe and effective oral treatment curing both acute and chronic HAT and that could be implemented at the primary health care level. To complete the preclinical development and meet the regulatory requirements before initiating human trials, the anti-parasitic properties and the pharmacokinetic, metabolic and toxicological profile of fexinidazole have been assessed. METHODS AND FINDINGS: Standard in vitro and in vivo anti-parasitic activity assays were conducted to assess drug efficacy in experimental models for HAT. In parallel, a full range of preclinical pharmacology and safety studies, as required by international regulatory guidelines before initiating human studies, have been conducted. Fexinidazole is moderately active in vitro against African trypanosomes (IC₅₀ against laboratory strains and recent clinical isolates ranged between 0.16 and 0.93 µg/mL) and oral administration of fexinidazole at doses of 100 mg/kg/day for 4 days or 200 mg/kg/day for 5 days cured mice with acute and chronic infection respectively, the latter being a model for the advanced and fatal stage of the disease when parasites have disseminated into the brain. In laboratory animals, fexinidazole is well absorbed after oral administration and readily distributes throughout the body, including the brain. The absolute bioavailability of oral fexinidazole was 41% in mice, 30% in rats, and 10% in dogs. Furthermore, fexinidazole is rapidly metabolised in vivo to at least two biologically active metabolites (a sulfoxide and a sulfone derivative) that likely account for a significant portion of the therapeutic effect. Key pharmacokinetic parameter after oral absorption in mice for fexinidazole and its sulfoxide and sulfone metabolites are a C(max) of 500, 14171 and 13651 ng/mL respectively, and an AUC₀₋₂₄ of 424, 45031 and 96286 h.ng/mL respectively. Essentially similar PK profiles were observed in rats and dogs. Toxicology studies (including safety pharmacology and 4-weeks repeated-dose toxicokinetics in rat and dog) have shown that fexinidazole is well tolerated. The No Observed Adverse Event Levels in the 4-weeks repeated dose toxicity studies in rats and dogs was 200 mg/kg/day in both species, with no issues of concern identified for doses up to 800 mg/kg/day. While fexinidazole, like many nitroheterocycles, is mutagenic in the Ames test due to bacterial specific metabolism, it is not genotoxic to mammalian cells in vitro or in vivo as assessed in an in vitro micronucleus test on human lymphocytes, an in vivo mouse bone marrow micronucleus test, and an ex vivo unscheduled DNA synthesis test in rats. CONCLUSIONS: The results of the preclinical pharmacological and safety studies indicate that fexinidazole is a safe and effective oral drug candidate with no untoward effects that would preclude evaluation in man. The drug has entered first-in-human phase I studies in September 2009. Fexinidazole is the first new clinical drug candidate with the potential for treating advanced-stage sleeping sickness in thirty years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised methods for the Salmonella mutagenicity test
Maron, D. M., & Ames, B. N. (1983) · Mutation Research/Environmental Mutagenesis and Related Subjects · doi:10.1016/0165-1161(83)90010-9 · Cited by 7,386
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
Reduction potentials of one-electron couples involving free radicals in aqueous solution
Wardman, P. (1989) · Journal of Physical and Chemical Reference Data · doi:10.1063/1.555843 · Cited by 2,123
Cytokinesis-block micronucleus cytome assay
Fenech, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.77 · Cited by 2,019
Irwin, S. (1968) · Psychopharmacologia · doi:10.1007/bf00401402 · Cited by 1,234
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Brun, R., Blum, J., Chappuis, F., & Burri, C. (2010) · The Lancet · doi:10.1016/s0140-6736(09)60829-1 · Cited by 926
Self-citationThe prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030466 · Cited by 751
Räz, B., Iten, M., Grether-Bühler, Y., Kaminsky, R., & Brun, R. (1997) · Acta Tropica · doi:10.1016/s0001-706x(97)00079-x · Cited by 688
Self-citationSection XXIV. Partition Chromatographs
(2009) · Biotechnology · doi:10.1201/9781420084498-31 · Cited by 590
Baltz, T., Baltz, D., Giroud, C., & Crockett, J. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03772.x · Cited by 562
Priotto, G., Kasparian, S., Mutombo, W., Ngouama, D., Ghorashian, S., Arnold, U., Ghabri, S., Baudin, E., Buard, V., Kazadi-Kyanza, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61117-x · Cited by 533
Self-citationMetronidazole: A Therapeutic Review and Update
Freeman, C. D., Klutman, N. E., & Lamp, K. C. (1997) · Drugs · doi:10.2165/00003495-199754050-00003 · Cited by 473
In vivo rodent micronucleus assay: protocol, conduct and data interpretation
Krishna, G., & Hayashi, M. (2000) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(00)00117-2 · Cited by 465
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes
Wilkinson, S. R., Taylor, M. C., Horn, D., Kelly, J. M., & Cheeseman, I. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711014105 · Cited by 457
Mutagenicity of Nitroaromatic Compounds
Purohit, V., & Basu, A. K. (2000) · Chemical Research in Toxicology · doi:10.1021/tx000002x · Cited by 450
Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next?
Simarro, P. P., Jannin, J., & Cattand, P. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050055 · Cited by 439
Evaluation of the MDR-MDCK cell line as a permeability screen for the blood–brain barrier
Wang, Q., Rager, J. D., Weinstein, K., Kardos, P. S., Dobson, G. L., Li, J., & Hidalgo, I. J. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.10.007 · Cited by 348
Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease
Barrett, M. P., Boykin, D. W., Brun, R., & Tidwell, R. R. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707354 · Cited by 338
Self-citationHuman African trypanosomiasis of the CNS: current issues and challenges
Kennedy, P. G. E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421052 · Cited by 327
Principles of Safety Pharmacology
Pugsley, M. K., Authier, S., & Curtis, M. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.280 · Cited by 250
Dierks, E. A., Stams, K. R., Lim, H., Cornelius, G., Zhang, H., & Ball, S. E. (2001) · PubMed · Cited by 236
Role of Caco-2 Cell Monolayers in Prediction of Intestinal Drug Absorption
Shah, P., Jogani, V., Bagchi, T., & Misra, A. (2006) · Biotechnology Progress · doi:10.1021/bp050208u · Cited by 233
McCoy, E. C., Rosenkranz, H. S., & Mermelstein, R. (1981) · Environmental Mutagenesis · doi:10.1002/em.2860030403 · Cited by 156
On the mutagenicity of nitroimidazoles
Voogd, C. E. (1981) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/0165-1110(81)90006-3 · Cited by 146
Human African trypanosomiasis (sleeping sickness): epidemiological update.
(2006) · PubMed · Cited by 135
Benfenati, E., Benigni, R., DeMarini, D. M., Helma, C., Kirkland, D., Martin, T. M., Mazzatorta, P., Ouédraogo, G., RICHARD, A. M., Schilter, B., et al. (2009) · Journal of Environmental Science and Health Part C · doi:10.1080/10590500902885593 · Cited by 128
Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis
Barry, C. E., Boshoff, H. I., & Dowd, C. S. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383214 · Cited by 128
Wenzler, T., Boykin, D. W., Ismail, M. A., Hall, J. E., Tidwell, R. R., & Brun, R. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00225-09 · Cited by 124
Self-citationKirkland, D., Aardema, M. J., Banduhn, N., Carmichael, P. L., Fautz, R., Meunier, J. R., & Pfuhler, S. (2007) · Mutagenesis · doi:10.1093/mutage/gem006 · Cited by 118
Chappuis, F., Udayraj, N., Stietenroth, K., Meussen, A., & BOVIER, P. A. (2005) · Clinical Infectious Diseases · doi:10.1086/432576 · Cited by 118
Thuita, J. K., Karanja, S. M., Wenzler, T., Mdachi, R. E., Ngotho, J. M., Kagira, J. M., Tidwell, R. R., & Brun, R. (2008) · Acta Tropica · doi:10.1016/j.actatropica.2008.07.006 · Cited by 98
Self-citationHTS and hit finding in academia – from chemical genomics to drug discovery
Frearson, J. A., & Collie, I. T. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.004 · Cited by 91
Melarsoprol refractory T. b. gambiense from Omugo, north‐western Uganda
Matovu, E., Enyaru, J., Legros, D., Schmid, C., Seebeck, T., & Kaminsky, R. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00712.x · Cited by 74
Activity of Megazol, a Trypanocidal Nitroimidazole, Is Associated with DNA Damage
Enanga, B., Ariyanayagam, M. R., Stewart, M. L., & Barrett, M. P. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3368-3370.2003 · Cited by 61
Human African Trypanosomiasis in Areas without Surveillance
Chappuis, F., Lima, M. A., Flévaud, L., & Ritmeijer, K. (2010) · Emerging infectious diseases · doi:10.3201/eid1602.090967 · Cited by 38
Safety pharmacology of the respiratory system: Techniques and study design
Murphy, D. J. (1994) · Drug Development Research · doi:10.1002/ddr.430320408 · Cited by 37
Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound
Suter, W., Hartmann, A., Poetter, F., Sagelsdorff, P., Hoffmann, P., & Martus, H. (2002) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/s1383-5718(02)00105-5 · Cited by 37
NECT trial: more than a small victory over sleeping sickness
Opigo, J., & Woodrow, C. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61163-6 · Cited by 25
Cited by
Brun, R., Blum, J., Chappuis, F., & Burri, C. (2010) · The Lancet · doi:10.1016/s0140-6736(09)60829-1 · Cited by 926
Self-citationClinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)
Kennedy, P. G. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70296-x · Cited by 442
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., De Rycker, M., Torrie, L. S., Wyatt, P. G., Wyllie, S., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.193 · Cited by 421
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis
Nagle, A. S., Khare, S., Kumar, A. B., Supek, F., Buchynskyy, A., Mathison, C. J. N., Chennamaneni, N. K., Pendem, N., Buckner, F. S., Gelb, M. H., et al. (2014) · Chemical Reviews · doi:10.1021/cr500365f · Cited by 348
Chagas Disease Drug Discovery: Toward a New Era
Chatelain, E. (2015) · SLAS Discovery · doi:10.1177/1087057114550585 · Cited by 312
Metadata
- Authors
- Torreele, E., Bourdin Trunz, B., Tweats, D., Kaiser, M., Brun, R., Mazué, G., Bray, M. A., & Pécoul, B.
- Venue
- PLoS Neglected Tropical Diseases
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-12-21
- Volume
- 4
- Issue
- 12
- Pages
- e923
- ISSN
- 1935-2727 (ISSN-L)
- 1935-2735
- OpenAlex
- W1987565779
- Cited by
- 325
- References
- 42
- FWCI
- 13.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.